Ocugen Inc., an ophthalmic biopharmaceutical company based in Pennsylvania, USA, has announced the close of a $7.5M venture capital funding to support the development of… Read More »Ophthalmic biopharmaceutical company raises $7.5M for the development of new treatments for sight-threatening disorders
Dutch biotechnology company uniQure B.V., (NASDAQ:QURE), Amsterdam, The Netherlands, has announced that it will not pursue the renewal of its Glybera (alipogene tiparvovec) marketing authorization… Read More »Uncertainty for gene therapy following withdrawal from market of Europe’s first gene therapeutic
Dutch biotechnology company ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, The Netherlands, has announced the receipt of “fast-track” designation from the FDA for their clinical stage development… Read More »Dutch company ProQR announces the receipt of FDA authorisation to initiate Phase I/II study for Leber congenital amaurosis, type 10 (LCA10)
Spark Therapeutics (NASDAQ:ONCE), Philadelphia, PA, has announced the filing of a rolling Biologics License Application (BLA) with the US FDA for their novel gene therapy… Read More »Spark Therapeutics files rolling BLA with FDA for new gene therapy product to treat RPE-mediated retinal degeneration
RegenxBio Inc. (NASDAQ:RGNX), Rockville, Maryland, USA, has announced the successful raising of $75.9 million through the sale of 3.7 million shares at $20.50/share in a… Read More »RegenxBio Inc. (NASDAQ:RGNX) raises additional investment funds as long term product for novel wet AMD study enters phase I clinical testing.
A UK newspaper, The Guardian, has reported that EU officials will shortly be scheduling the transfer of EU agencies out of the UK as part… Read More »EMA exit from London may be sooner than originally anticipated creating additional uncertainty for drug approvals
A UK clinical stage biotech company, NightstaRx, has announced the enrolment of the first patient in a Phase I / II gene therapy study for… Read More »UK gene therapy company, NightstaRx Ltd., launches Phase I / II gene therapy study for treatment of X-linked retinitis pigmentosa
Allergan Inc. (NASDAQ:AGN) and Editas Medicine Inc. (NASDAQ:EDIT) have announced the execution of an exclusive licensing transaction in which Allergan receives an option on up… Read More »Allergan (NYSE:AGN) and CRISPR company, Editas Medicine Inc. (NASDAQ:EDIT), announce strategic deal to focus on eye diseases
AGTC Inc (NASDAQ: AGTC) based in Gainesville, Florida and Bionic Sight LLC, based in New York, have announced a strategic collaboration to develop opogenetic therapies… Read More »AGTC and Bionic Sight announce a strategic collaboration to use optogenetics and neuroprosthetics, together with specific software, to improve visual perception
GenSight Biologics S.A. (Euronext: SIGHT) has announced the receipt of FDA Orphan Drug Designation in the US for its experimental retinitis pigmentosa (RP) treatment, “GS030”.… Read More »GenSight, a French biotechnology company, has announced the receipt of FDA orphan designation for retinitis pigmentosa gene therapy treatment in the US.